FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194128575> ?p ?o ?g. }

• W3194128575 endingPage "3673" @default.
• W3194128575 startingPage "3661" @default.
• W3194128575 abstract "Avitinib is the first third-generation epithelial growth factor receptor (EGFR) inhibitor independently developed in China and is mainly used for treating non-small cell lung cancer. However, pharmacokinetic details are limited. This study explored the in vivo and in vitro effects of avitinib on cytochrome CYP450 enzymes metabolic activity.A rapid and sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for determining six probe substrates and their metabolites. Avitinib influence on activity levels of CYP isozymes was examined in vitro using human and rat liver microsomes (HLMs/RLMs). For in vivo studies, rats were pretreated with 30 mg/kg avitinib once daily for 7 days (avitinib multiple-doses group), 30 mg/kg avitinib on day 7 (avitinib single-dose group), or an equivalent amount of CMC-Na once daily for 7 days (control group), followed by intragastrical administration of the probe substrates (1 mg/kg tolbutamide and 10 mg/kg phenacetin, bupropion, chlorzoxazone, dextromethorphan, and midazolam). Plasma pharmacokinetics and IC50 values of the probe substrates were then compared. Pharmacokinetic parameters were determined using non-compartmental analysis implemented in a pharmacokinetic program.In vitro experiments revealed different inhibitory effects of avitinib on the six probe substrates with various IC50 values (bupropion, 6.39/22.64 μM; phenacetin, 15.79/48.36 μM; chlorzoxazone, 23.15/57.09 μM; midazolam, 27.64/59.6 μM; tolbutamide, 42.18/6.91 μM; dextromethorphan, 44.39/56.57 μM, in RLMs and HLMs respectively). In vivo analysis revealed significant differences (P <0.05) in distinct pharmacokinetic parameters (AUC(0-t), AUC (0-∞), Cmax, MRT(0-t), MRT (0-∞), and CLz/F) for the six probe substrates after avitinib pretreatment.A sensitive and reliable UPLC-MS/MS method was established to determine the concentration of six probe substrates in rat plasma. Avitinib had inhibitory effects on CYP450 enzymes, especially cyp2b1, cyp1a2 in RLMs, CYP2C9 in HLMs, and cyp1a2, cyp2b1, cyp2d1, and cyp2e1 in vivo. Our data recommend caution when avitinib was taken simultaneously with drugs metabolized by CYP450 enzymes." @default.
• W3194128575 created "2021-08-30" @default.
• W3194128575 creator A5000566844 @default.
• W3194128575 creator A5017775643 @default.
• W3194128575 creator A5030399315 @default.
• W3194128575 creator A5044244867 @default.
• W3194128575 creator A5061642120 @default.
• W3194128575 creator A5062501354 @default.
• W3194128575 creator A5074187211 @default.
• W3194128575 creator A5078477224 @default.
• W3194128575 creator A5091210737 @default.
• W3194128575 date "2021-08-01" @default.
• W3194128575 modified "2023-10-14" @default.
• W3194128575 title "Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats" @default.
• W3194128575 cites W1575841833 @default.
• W3194128575 cites W1576422728 @default.
• W3194128575 cites W186154380 @default.
• W3194128575 cites W1994904603 @default.
• W3194128575 cites W2017577604 @default.
• W3194128575 cites W2020184426 @default.
• W3194128575 cites W2042017971 @default.
• W3194128575 cites W2043515466 @default.
• W3194128575 cites W2067141256 @default.
• W3194128575 cites W2109257139 @default.
• W3194128575 cites W2143208566 @default.
• W3194128575 cites W2146506502 @default.
• W3194128575 cites W2288759296 @default.
• W3194128575 cites W2491986266 @default.
• W3194128575 cites W2513491150 @default.
• W3194128575 cites W2526148036 @default.
• W3194128575 cites W2592849643 @default.
• W3194128575 cites W2594731529 @default.
• W3194128575 cites W2600480382 @default.
• W3194128575 cites W2612204471 @default.
• W3194128575 cites W2795832970 @default.
• W3194128575 cites W2895926103 @default.
• W3194128575 cites W2901491542 @default.
• W3194128575 cites W2903084459 @default.
• W3194128575 cites W2924566935 @default.
• W3194128575 cites W2942402550 @default.
• W3194128575 cites W2960526138 @default.
• W3194128575 cites W2980563832 @default.
• W3194128575 cites W2998801442 @default.
• W3194128575 cites W3006121680 @default.
• W3194128575 cites W3007685712 @default.
• W3194128575 cites W3024964423 @default.
• W3194128575 cites W3045844891 @default.
• W3194128575 cites W3080221508 @default.
• W3194128575 doi "https://doi.org/10.2147/dddt.s323186" @default.
• W3194128575 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8387736" @default.
• W3194128575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34456561" @default.
• W3194128575 hasPublicationYear "2021" @default.
• W3194128575 type Work @default.
• W3194128575 sameAs 3194128575 @default.
• W3194128575 citedByCount "4" @default.
• W3194128575 countsByYear W31941285752022 @default.
• W3194128575 countsByYear W31941285752023 @default.
• W3194128575 crossrefType "journal-article" @default.
• W3194128575 hasAuthorship W3194128575A5000566844 @default.
• W3194128575 hasAuthorship W3194128575A5017775643 @default.
• W3194128575 hasAuthorship W3194128575A5030399315 @default.
• W3194128575 hasAuthorship W3194128575A5044244867 @default.
• W3194128575 hasAuthorship W3194128575A5061642120 @default.
• W3194128575 hasAuthorship W3194128575A5062501354 @default.
• W3194128575 hasAuthorship W3194128575A5074187211 @default.
• W3194128575 hasAuthorship W3194128575A5078477224 @default.
• W3194128575 hasAuthorship W3194128575A5091210737 @default.
• W3194128575 hasBestOaLocation W31941285751 @default.
• W3194128575 hasConcept C112705442 @default.
• W3194128575 hasConcept C126322002 @default.
• W3194128575 hasConcept C140027455 @default.
• W3194128575 hasConcept C142724271 @default.
• W3194128575 hasConcept C150903083 @default.
• W3194128575 hasConcept C181199279 @default.
• W3194128575 hasConcept C185592680 @default.
• W3194128575 hasConcept C202751555 @default.
• W3194128575 hasConcept C207001950 @default.
• W3194128575 hasConcept C2775922563 @default.
• W3194128575 hasConcept C2776054734 @default.
• W3194128575 hasConcept C2776658834 @default.
• W3194128575 hasConcept C2776814716 @default.
• W3194128575 hasConcept C2777843972 @default.
• W3194128575 hasConcept C2778000748 @default.
• W3194128575 hasConcept C2778162141 @default.
• W3194128575 hasConcept C2779306644 @default.
• W3194128575 hasConcept C2779908668 @default.
• W3194128575 hasConcept C2781245242 @default.
• W3194128575 hasConcept C43617362 @default.
• W3194128575 hasConcept C526171541 @default.
• W3194128575 hasConcept C55493867 @default.
• W3194128575 hasConcept C71924100 @default.
• W3194128575 hasConcept C86745063 @default.
• W3194128575 hasConcept C86803240 @default.
• W3194128575 hasConcept C87644729 @default.
• W3194128575 hasConcept C98274493 @default.
• W3194128575 hasConceptScore W3194128575C112705442 @default.
• W3194128575 hasConceptScore W3194128575C126322002 @default.
• W3194128575 hasConceptScore W3194128575C140027455 @default.

• next